4
Participants
Start Date
November 30, 2014
Primary Completion Date
September 30, 2018
Study Completion Date
September 30, 2018
Ranibizumab,
Intravitreal injection of Ranibizumab as treatment for acute pseudophakic cystoid macular edema. Ranibizumab patients will receive three monthly Ranibizumab 0.5 mg/0.05 mL injections, followed by PRN dosing, as treatment for acute pseudophakic cystoid macular edema.
Triamcinolone acetonide
Intravitreal injection of Triamcinolone acetonide as treatment for acute pseudophakic cystoid macular edema. Triamcinolone acetonide patients will receive PRN Triamcinolone acetonide 4 mg/0.1 mL injections, every 3 months, as treatment for acute pseudophakic cystoid macular edema.
Soll Eye, Philadelphia
Collaborators (1)
Genentech, Inc.
INDUSTRY
Soll Eye
OTHER